{
}
Goldman Sachs has lowered its price target for Merck & Co., Inc. to $99 from $103 while maintaining a Buy rating. Merck specializes in therapeutic products and vaccines, with net sales primarily from pharmaceuticals (67%), vaccines (22.1%), and animal health products (9.4%). Geographically, sales are led by the United States (47.4%), followed by Europe/Middle East/Africa (22%) and China (11.3%).
UBS has maintained a Buy rating on Merck with a price target of $105, despite concerns over Gardasil sales projections, which UBS estimates at $1.3 billion for Q1, below the consensus of $1.4 billion. Merck's strong fundamentals include a 77% gross profit margin and a robust EBITDA of $29.1 billion. Upcoming events, such as the reassessment of Gardasil demand in China and the Phase 3 CORALreef study results, are seen as potential inflection points for investor interest.
UBS analyst Trung Huynh has reaffirmed a Buy rating on Merck (NYSE: MRK) with a price target of $105.00. The analyst noted positive sentiment surrounding the company, indicating confidence in its future performance.
UBS warns that the healthcare sector remains vulnerable despite President Trump's recent announcements, which did not initially target the pharmaceutical industry with tariffs. Trump indicated that pharmaceutical companies must return to the U.S. or face significant taxes, suggesting potential future tariffs or tax reforms. UBS identifies Abbvie and Merck as likely beneficiaries of these developments.
The Goldman Sachs Group reported a strong quarterly performance with earnings per share of $11.95, exceeding estimates, and a revenue of $13.87 billion, up 22.5% year-over-year. Despite a Hold rating from analysts, several firms have adjusted their price targets, with an average target of $590.60. The company also announced a quarterly dividend of $3.00, yielding 2.21%.
Summit Securities Group LLC acquired a new stake in The Goldman Sachs Group, purchasing 14,600 shares valued at approximately $8.36 million, making it the firm's 7th largest position. Insider trading saw significant sales, with Kathryn H. Ruemmler selling 7,498 shares for nearly $4.76 million. The company reported strong quarterly earnings, beating estimates with $11.95 EPS and a revenue of $13.87 billion, reflecting a 22.5% year-over-year increase.
Goldman Sachs has raised its price target for AstraZeneca shares to £151.30, maintaining a Conviction Buy rating, citing an 18% revenue growth and potential in the oral PCSK9 inhibitor market with AZD0780. The anticipated Phase 2 PURSUIT trial data, due on March 31, 2025, is expected to significantly impact the competitive landscape. AstraZeneca is also investing $2.5 billion in a new R&D center in Beijing, enhancing its presence in China and focusing on early-stage research and clinical development.
The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.
Pfizer's shares have shown mixed performance recently, with a slight decline to EUR 24.50 on February 13, 2025, following a positive trading day that saw a rise to EUR 25.22. The company reported a 7% increase in annual revenue to $63.6 billion for 2024, driven by strong sales of Covid-19 drugs and other key products, while maintaining a shareholder-friendly dividend policy. Analysts have adjusted their price targets, with ratings ranging from "Buy" to "Neutral," reflecting a cautious but optimistic outlook for 2025.
Pfizer is navigating challenges, including a reinstated lawsuit affecting its diversity fellowship program, which has pressured its share price. As of January 9, 2025, shares closed at EUR 26.03, reflecting a slight decline, while UBS and JPMorgan maintain a "Neutral" rating with price targets of USD 29 and USD 30, respectively. Despite uncertainties, Pfizer reported strong fourth-quarter results, exceeding expectations with revenues of $17.76 billion, and is targeting sales of $61 to $64 billion for 2025.
Merck & Co., Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
goldman sachs lowers merck price target while maintaining buy rating
15:54 25.04.2025
ubs maintains buy rating for merck with price target of 105 dollars
16:43 03.04.2025
ubs maintains buy rating and price target for merck
15:45 03.04.2025
pharmaceutical sector faces uncertainty amid potential tariffs and tax changes
10:50 03.04.2025
goldman sachs group reports strong earnings but analysts suggest better investment options
12:40 31.03.2025
goldman sachs reports strong quarterly earnings and dividend announcement
Merck & Co., Inc.
Morgan Stanley
Wells Fargo & Company
UBS Group AG
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Citigroup Inc.
USA
Show more
12:06 30.03.2025
Goldman Sachs raises AstraZeneca target amid promising drug development and expansion
08:50 28.03.2025
high potency active pharmaceutical ingredients market trends and future growth prospects
Merck & Co., Inc.
Roche Diagnostics AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
BASF AG
Novartis International AG
Lonza Group AG
Bristol-Myers Squibb Co
Cambrex Corporation
Seqens
Pfizer Inc.
Sanofi Aventis SA
Bayer AG
CARBOGEN AMCIS AG
Alice Mutum
Viju Shah
Show more
10:02 26.03.2025
Pfizer reports strong fourth quarter results and maintains positive 2025 outlook
14:10 13.02.2025
Pfizer faces challenges as share price shows mixed performance in 2025
United States Dollar
Euro
Merck & Co., Inc.
Pfizer Inc.
USA
CHE
Albert Bourla
Chris Schott
Raphael Schicho
Akash Tewari
Show more
16:00 04.02.2025
Trending
Subcategory
Stock Market Updates
Industry Trends
Corporate News
Retail and Consumer Goods
Finance Mergers & Acquisitions
Global Financial Events
Startups & Entrepreneurship
Government Policies
Market Analysis and Predictions
AI Innovations
Industry Mergers & Acquisitions
Central Bank Actions
Domestic Politics
Banking Regulations
Supply Chain Management
Global Trade Developments
Funding Rounds & Investments
Cryptocurrency Trends
Hedge Funds & Private Equity
Emerging Startups
Countries:
Companies:
NVIDIA Corporation
Tesla, Inc.
Apple Inc.
American Express Co
Huawei Technologies CO. Ltd.
The Goldman Sachs Group, Inc.
Bank of America Corporation
Citigroup Inc.
Barclays PLC
Wells Fargo & Company
HSBC Holdings plc
International Monetary Fund FUND
Coca-Cola FEMSA, S.A.B. de C.V.
Nintendo Co., Ltd.
Raiffeisen Bank International AG
Berkshire Hathaway Inc.
Pfizer Inc.
Williams-Sonoma, Inc.
Morgan Stanley
Casa DOS Ventos SA
Currencies:
United States Dollar
Euro
Japanese Yen
United Arab Emirates Dirham
Chinese Yuan
British Pound Sterling
Offshore Chinese Yuan
Indian Rupee
Swiss Franc
Brazilian Real
Saudi Riyal
Australian Dollar
South Korean Won
Hong Kong Dollar
People: